• 1. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 2. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555

Introduction to 3-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-ylpentan-1-amine (CAS No. 1006340-62-0) and Its Emerging Applications in Chemical Biology and Medicinal Chemistry

The compound 3-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-ylpentan-1-amine (CAS No. 1006340-62-0) represents a fascinating molecular scaffold that has garnered significant attention in the fields of chemical biology and medicinal chemistry. This heterocyclic amine, characterized by its unique structural features—including a trifluoromethyl group and a pyrazole core—has emerged as a versatile building block for the development of novel therapeutic agents. The strategic incorporation of these functional groups not only enhances the compound's metabolic stability but also modulates its pharmacokinetic properties, making it an attractive candidate for further exploration.

Recent advancements in synthetic chemistry have enabled the efficient preparation of this compound, leveraging modern methodologies such as transition-metal-catalyzed cross-coupling reactions and fluorination techniques. These innovations have not only improved yield but also allowed for the introduction of additional modifications, expanding its potential utility in drug discovery. The pyrazole moiety, known for its broad spectrum of biological activities, has been extensively studied for its role in modulating enzyme inhibition and receptor binding. In particular, derivatives of pyrazole have shown promise in the treatment of inflammatory diseases, infectious disorders, and even certain types of cancer.

The presence of a methyl group at the 3-position of the pyrazole ring further enhances the compound's reactivity, enabling further derivatization through nucleophilic substitution or condensation reactions. This flexibility is particularly valuable when designing molecules that require specific interactions with biological targets. Furthermore, the trifluoromethyl substituent—a well-documented pharmacophore—improves lipophilicity and binding affinity, which are critical factors in drug design. This combination of structural features makes 3-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-ylpentan-1-amine a compelling candidate for exploring new therapeutic modalities.

In the realm of medicinal chemistry, this compound has been investigated for its potential as an intermediate in the synthesis of kinase inhibitors. Kinases play a pivotal role in cellular signaling pathways, and their dysregulation is implicated in numerous diseases, including cancer. By targeting specific kinases, small molecules derived from this scaffold could disrupt aberrant signaling networks and restore normal cellular function. Preliminary studies have demonstrated that analogs of this compound exhibit inhibitory activity against several kinases, with IC50 values ranging from nanomolar to micromolar concentrations. Such findings underscore its significance as a lead compound for further optimization.

Another area where this compound has shown promise is in the development of antimicrobial agents. The increasing prevalence of antibiotic-resistant pathogens has necessitated the discovery of novel antimicrobial compounds with unique mechanisms of action. The structural features of 3-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-ylpentan-1-amine, particularly its ability to interact with bacterial enzymes and disrupt metabolic pathways, make it a promising candidate for combating resistant strains. Recent computational studies have identified potential binding pockets on bacterial enzymes that could be targeted by derivatives of this compound, providing a rational framework for structure-based drug design.

The synthesis of this compound also highlights advancements in green chemistry principles. Modern synthetic routes emphasize efficiency, sustainability, and minimal waste generation—key considerations in industrial-scale production. For instance, catalytic fluorination methods have been developed that reduce reliance on hazardous reagents while maintaining high yields. These innovations align with global efforts to promote environmentally responsible chemical manufacturing practices.

Furthermore, the pharmacokinetic properties of 3-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-ylpentan-1-amine have been carefully evaluated through preclinical studies. These investigations have revealed favorable absorption, distribution, metabolism, and excretion (ADME) profiles, suggesting potential for oral administration and systemic bioavailability. Such characteristics are essential for translating laboratory findings into viable therapeutic options for patients.

The versatility of this scaffold also extends to its application in material science and agrochemicals. By modifying its functional groups or incorporating additional heterocycles, researchers can tailor its properties for specialized applications. For example, derivatives with enhanced photostability or solubility could be developed for use in photodynamic therapy or as intermediates in crop protection agents.

In conclusion,3-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-y pentan -1 -amine (CAS No. 1006340 -62 -0) stands as a testament to the ingenuity inherent in modern chemical synthesis and drug discovery. Its unique structural attributes—combining a pyrazole core with a trifluoromethyl group—position it as a valuable asset in developing novel therapeutics across multiple disease domains. As research continues to uncover new applications and synthetic strategies, this compound is poised to play an increasingly significant role in advancing human health and addressing global challenges in medicine and chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)